钾离子通道在低氧性肺动脉高压中的作用及药物干预研究进展

doi:10.11958/20221822

天津医药 ›› 2023, Vol. 51 ›› Issue (8): 892-896.doi: 10.11958/20221822

• 综述 • 上一篇

钾离子通道在低氧性肺动脉高压中的作用及药物干预研究进展

张朝霞¹^,²(), 南星梅¹, 李占强¹, 芦殿香¹^,³^,^△()

1 青海大学高原医学研究中心，高原医学教育部重点实验室，青海省高原医学应用基础重点实验室，青海-犹他高原医学联合重点实验室（邮编810001）
2 青海卫生职业技术学院
3 成都大学附属医院中心实验室

收稿日期:2022-11-07 修回日期:2023-03-12 出版日期:2023-08-15 发布日期:2023-08-10
通讯作者: ^△E-mail：ludianxiang@126.com
作者简介:张朝霞（1973），女，教授，博士在读，主要从事抗缺氧中藏药物方面研究。E-mail：837695235@qq.com
基金资助:
国家自然科学基金资助项目(81860768);国家自然科学基金资助项目(82060786);国家自然科学基金资助项目(32060088);青海省科技厅自然科学基金面上项目(2021-ZJ-907);高原医学教育部重点实验室-青海省高原医学应用基础重点实验室（青海-犹他高原医学联合重点实验室）开放课题资助项目(2022-KF-01);青海省“昆仑英才·教学名师”人才项目;青海省“昆仑英才·高端创业人才”项目

Research progress on the role of potassium channels and drug intervention in hypoxic pulmonary hypertension

ZHANG Zhaoxia¹^,²(), NAN Xingmei¹, LI Zhanqiang¹, LU Dianxiang¹^,³^,^△()

1 Research Center for High Altitude Medicine, Qinghai University, Key Laboratory of High Altitude Medicine, Ministry of Education, Key Laboratory of Application and Foundation for High Altitude Medicine Research in Qinghai Province, Qinghai-Utah Joint Research Key Lab for High Altitude Medicine, Xining 810001, China
2 Qinghai Health Insitutu of Sciences
3 Central Laboratory, Clinical Medical College & Affiliated Hospital of Chengdu University

Received:2022-11-07 Revised:2023-03-12 Published:2023-08-15 Online:2023-08-10
Contact: ^△E-mail: ludianxiang@126.com

张朝霞, 南星梅, 李占强, 芦殿香. 钾离子通道在低氧性肺动脉高压中的作用及药物干预研究进展[J]. 天津医药, 2023, 51(8): 892-896.

ZHANG Zhaoxia, NAN Xingmei, LI Zhanqiang, LU Dianxiang. Research progress on the role of potassium channels and drug intervention in hypoxic pulmonary hypertension[J]. Tianjin Medical Journal, 2023, 51(8): 892-896.

摘要/Abstract

摘要：

钾离子（K⁺）通道是位于细胞膜上的一种跨膜蛋白，血管平滑肌细胞K⁺通道通过膜电位在血管张力、细胞兴奋性和细胞增殖等方面发挥重要调控作用。肺动脉平滑肌细胞K⁺通道功能障碍与低氧性肺动脉高压（HPH）的病理进程密切相关，K⁺通道有望成为HPH的治疗靶点。对肺动脉平滑肌细胞K⁺通道的种类以及在HPH中的研究进展、相关干预药物进行综述，旨在为HPH的发病机制研究和药物研发提供新思路。

关键词: 肺动脉高压, 低氧, 钾通道, 肌细胞, 平滑肌, 低氧性肺血管收缩, 低氧性肺血管重构, 药物干预

Abstract:

Potassium ion (K⁺) channel is a transmembrane protein located on cell membrane. The K⁺channels of vascular smooth muscle cells play an important role in regulating vascular tension, cell excitability and proliferation through membrane potential. The dysfunction of K⁺channels in pulmonary artery smooth muscle cells (PASMCs) is closely related to the pathological process of hypoxic pulmonary hypertension (HPH), and K⁺channels are expected to become the therapeutic target of HPH. In this artical, types of K⁺channels in PASMCs, the research progress of K⁺channels in HPH and drugs that interfere with HPH were reviewed, in order to provide new ideas for the pathogenesis research and drug development of HPH.

Key words: pulmonary arterial hypertension, hypoxia, potassium channels, myocytes, smooth muscle, hypoxic pulmonary vasoconstriction, hypoxic pulmonary vascular remodeling, drug intervention

中图分类号:

R544.16

参考文献 41

[1]	中华医学会呼吸病学分会肺栓塞与肺血管病学组, 中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会, 全国肺栓塞与肺血管病防治协作组, 等. 中国肺动脉高压诊断与治疗指南(2021版)[J]. 中华医学杂志, 2021, 101(1):11-51.
	The Pulmonary Embolism and Pulmonary Vascular Disease Group of Chinese Society of Respiratory Diseases, Chinese Medical Doctor Association Pulmonary Embolism and Pulmonary Vascular Disease Working Committee, National Cooperative Group for Prevention and Treatment of Pulmonary Embolism and Pulmonary Vascular Disease, et al. Chinese guidelines for the diagnosis and treatment of pulmonary hypertension(The 2021 version)[J]. Natl Med J China, 2021, 101(1):11-51. doi:10.3760/cma.j.cn112137-20201008-02778.
[2]	BRITO J, SIQUES P, PENA E. Long-term chronic intermittent hypoxia:a particular form of chronic high-altitude pulmonary hypertension[J]. Pulm Circ, 2020, 10(Suppl 1):5-12. doi:10.1177/2045894020934625.
[3]	MONDÉJAR-PARREÑO G, COGOLLUDO A, PEREZ-VIZCAINO F. Potassium(K⁺)channels in the pulmonary vasculature:implications in pulmonary hypertension physiological,pathophysiological and pharmacological regulation[J]. Harmacol Ther, 2021, 225:107835. doi:10.1016/j.pharmthera.2021.107835.
[4]	DOGAN M F, YILDIZ O, ARSLAN S O, et al. Potassium channels in vascular smooth muscle:a pathophysiological and pharmacological perspective[J]. Fundam Clin Pharmaco, 2019, 33(5):504-523. doi:10.1111/FCP.12461.
[5]	SONG S, BABICHEVA A, ZHAO T, et al. Notch enhances Ca⁽²⁺⁾ entry by activating calcium-sensing receptors and inhibiting voltage-gated K⁽⁺⁾ channelsAm J Physiol Cell Physiol, 2020, 318(5):954-968. doi:10.1152/ajpcell.00487.201.
[6]	DENG L, CHEN J, WANG T, et al. PDGF/MEK/ERK axis represses Ca⁽²⁺⁾ clearance via decreasing the abundance of plasma membrane Ca⁽²⁺⁾ pump PMCA4 in pulmonary arterial smooth muscle cells[J]. Am J Physiol Cell Physiol, 2021, 320(1):66-79. doi:10.1152/ajpcell.0290.2020.
[7]	MEI L, ZHENG Y M, SONG T, et al. Rieske iron-sulfur protein induces FKBP12.6/RyR2 complex remodeling and subsequent pulmonary hypertension through NF-κB/cyclin D1 pathway[J]. Nat Commun, 2020, 11(1):3527. doi:10.1038/s41467-020-17314-1.
[8]	HE Y, FANG X, SHI J, et al. Apigenin attenuates pulmonary hypertension by inducing mitochondria-dependent apoptosis of PASMCs via inhibiting the hypoxia inducible factor 1alpha-K_V1.5 channel pathway[J]. Chem Biol Interact, 2020, 317:108942. doi:10.1016/j.cbi.2020.108942.
[9]	ZHANG R, LI Z, LIU C, et al. Pretreatment with the active fraction of Rhodiola tangutica(Maxim.)S.H. Fu rescues hypoxia-induced potassium channel inhibition in rat pulmonary artery smooth muscle cells[J]. J Ethnopharmacol, 2022, 283:114734. doi:10.1016/j.jep.2021.114734.
[10]	MONDÉJAR-PARREÑO G, BARREIRA B, CALLEJO M, et al. Uncovered contribution of Kv7 channels to pulmonary vascular tone in pulmonary arterial hypertension[J]. Hypertension, 2020, 76(4):1134-1146. doi:10.1161/HYPERTENSIONAHA.120.15221.
[11]	WU W, LI Y, XU D Q. Role of ROS/Kv/HIF axis in the development of hypoxia-induced pulmonary hypertension[J]. Chin Med Sci J, 2017, 32(4):47-53. doi:10.24920/J1001-9294.2017.037.
[12]	BABICHEVA A, AYON R J, ZHAO T, et al. MicroRNA-mediated downregulation of K⁽⁺⁾channels in pulmonary arterial hypertension[J]. Am J Physiol Lung Cell Mol Physiol, 2020, 318(1):10-26. doi:10.1152/ajplung.00010.2019.
[13]	MONDÉJAR-PARREÑO G, CALLEJO M, BARREIRA B, et al. miR-1 is increased in pulmonary hypertension and downregulates Kv1.5 channels in rat pulmonary arteries[J]. J Physiol, 2019, 597(4):1185-1197. doi:10.1113/JP276054.
[14]	HAYABUCHI Y. The action of smooth muscle cell potassium channels in the pathology of pulmonary arterial hypertension[J]. Pediatr Cardiol, 2017, 38(1):1-14. doi:10.1007/s00246-016-1491-1497.
[15]	GUO S, SHEN Y, HE G, et al. Involvement of Ca⁽²⁺⁾-activated K⁽⁺⁾ channel 3.1 in hypoxia-induced pulmonary arterial hypertension and therapeutic effects of TRAM-34 in rats[J]. Biosci Rep, 2017,37(4):BSR20170763. doi:10.1042/BSR20170763.
[16]	MILARA J, BALLESTER B, MORELL A, et al. JAK2 mediates lung fibrosis,pulmonary vascular remodelling and hypertension in idiopathic pulmonary fibrosis:an experimental study[J]. Thorax, 2018, 73(6):519-529. doi:10.1136/thoraxjnl-2017-210728.
[17]	HU H, DING Y, WANG Y, et al. MitoK(ATP)channels promote the proliferation of hypoxic human pulmonary artery smooth muscle cells via the ROS/HIF/miR-210/ISCU signaling pathway[J]. Exp Ther Med, 2017, 14(6):6105-6112. doi:10.3892/etm.2017.5322.
[18]	PANDIT L M, LLOYD E E, REYNOLDS J O, et al. TWIK-2 channel deficiency leads to pulmonary hypertension through a Rho-kinase-mediated process[J]. Hypertension, 2014, 64(6):1260-1265. doi:10.1161/HYPERTENSIONAHA.114.03406.
[19]	CALLEJO M, MONDÉJAR-PARREÑO G, MORALES-CANO D, et al. Vitamin D deficiency downregulates TASK-1 channels and induces pulmonary vascular dysfunction[J]. Am J Physiol Lung Cell Mol Physiol, 2020, 319(4):627-640. doi:10.1152/ajplung.00475.2019.
[20]	HAN L, SONG N, HU X, et al. Inhibition of RELM-beta prevents hypoxia-induced overproliferation of human pulmonary artery smooth muscle cells by reversing PLC-mediated KCNK3 decline[J]. Life Sci, 2020, 246:117419. doi:10.1016/j.lfs.2020.117419.
[21]	LAMBERT M, CAPUANO V, BOET A, et al. Characterization of Kcnk3-mutated rat,a novel model of pulmonary hypertension[J]. Circ Res, 2019, 125(7):678-695. doi:10.1161/CIRCRESAHA.119.314793.
[22]	HAO X, LI H, ZHANG P, et al. Down-regulation of lncRNA Gas5 promotes hypoxia-induced pulmonary arterial smooth muscle cell proliferation by regulating KCNK3 expression[J]. Eur J Pharmacol, 2020, 889:173618. doi:10.1016/j.ejphar.2020.173618.
[23]	HUMBERT M, KOVACS G, HOEPER M M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension[J]. Eur Heart J, 2023, 61(1):2200879. doi:10.1183/13993003.00879-2022.
[24]	SITBON O, GOMBERG-MAITLAND M, GRANTON J, et al. Clinical trial design and new therapies for pulmonary arterial hypertension[J]. Eur Respir J, 2019, 53(1):1801908. doi:10.1183/13993003.01908-2018.
[25]	RUOPP N F, COCKRILL B A. Diagnosis and treatment of pulmonary arterial hypertension:a review[J]. JAMA, 2022, 327(14):1379-1391. doi:10.1001/jama.2022.4402.
[26]	PITRE T, SU J, CUI S, et al. Medications for the treatment of pulmonary arterial hypertension: a systematic review and network meta-analysis[J]. Eur Respir Rev, 2022, 31(165):220036. doi:10.1183/16000617.0036-2022.
[27]	CHRISTOU H, KHALIL R A. Mechanisms of pulmonary vascular dysfunction in pulmonary hypertension and implications for novel therapies[J]. Am J Physiol Heart Circ Physiol, 2022, 322(5):H702-H724. doi:10.1152/ajpheart.00021.2022.
[28]	LE RIBEUZ H, CAPUANO V, GIRERD B, et al. Implication of potassium channels in the pathophysiology of pulmonary arterial hypertension[J]. Biomolecules, 2020, 10(9):1261. doi:10.3390/biom10091261.
[29]	CUNNINGHAM K P, CLAPP L H, MATHIE A, et al. The prostacyclin analogue,treprostinil,used in the treatment of pulmonary arterial hypertension,is a potent antagonist of TREK-1 and TREK-2 potassium channels[J]. Front Pharmacol, 2021, 12:705421. doi:10.3389/fphar.2021.705421.
[30]	TIAN H, FAN F, GENG J, et al. Beraprost upregulates K_V channel expression and function via EP4 receptor in pulmonary artery smooth muscle cells obtained from rats with hypoxia-induced pulmonary hypertension[J]. J Vasc Res, 2019, 56(4):204-214. doi:10.1159/000500424.
[31]	MONDÉJAR-PARREÑO G, MORAL-SANZ J, BARREIRA B, et al. Activation of Kv7 channels as a novel mechanism for NO/cGMP-induced pulmonary vasodilation[J]. Br J Pharmacol, 2019, 176(13):2131-2145. doi:10.1111/bph.14662.
[32]	BOCK C, LINK A. How to replace the lost keys? Strategies toward safer K_V7 channel openers[J]. Future Med Chem, 2019. doi:10.4155/fmc-2018-0350.
[33]	RASHID J, NOZIK-GRAYCK E, MCMURTRY IF, et al. Inhaled combination of sildenafil and rosiglitazone improves pulmonary hemodynamics,cardiac function,and arterial remodeling[J]. Am J Physiol Lung Cell Mol Physiol, 2019, 316:119-130. doi:10.1152/ajplung.00381.2018.
[34]	HE M, CUI T, CAI Q, et al. Iptakalim ameliorates hypoxia-impaired human endothelial colony-forming cells proliferation,migration,and angiogenesis via Akt/eNOS pathways[J]. Pulm Circ, 2019, 9(3):2045894019875417. doi:10.1177/2045894019875417.
[35]	王江涛, 马博华, 沈会华, 等. 常山酮对高原肺动脉高压模型大鼠心肺功能的影响及其机制研究[J]. 天津医药, 2023, 51(1):41-44.
	WANG J T, MA B H, SHEN H H, et al. The effect of halofuginone on cardiopulmonary function and its mechanism in rats with high-altitude pulmonary hypertension[J]. Tianjin Med J, 2023, 51(1):41-44. doi:10.11958/20220965.
[36]	JAIN P P, ZHAO T, XIONG M, et al. Halofuginone,a promising drug for treatment of pulmonary hypertension[J]. Br J Pharmacol, 2021, 178(17):3373-3394. doi:10.1111/bph.15442.
[37]	FAN F, ZOU Y, WANG Y, et al. Sanguinarine reverses pulmonary vascular remolding of hypoxia-induced PH via survivin/HIF1α-attenuating Kv channels[J]. Front Pharmacol, 2021, 12:768513. doi:10.3389/fphar.2021.768513.
[38]	FUSI F, TREZZA A, TRAMAGLINO M, et al. The beneficial health effects of flavonoids on the cardiovascular system:focus on K⁽⁺⁾ channels[J]. Pharmacol Res, 2020, 152:104625. doi:10.1016/j.phrs.2019.104625.
[39]	DING L, JIA C, ZHANG Y, et al. Baicalin relaxes vascular smooth muscle and lowers blood pressure in spontaneously hypertensive rats[J]. Biomed Pharmacother, 2019, 111:325-330. doi:10.1016/j.biopha.2018.12.086.
[40]	LI W, DONG M, GUO P, et al. Luteolin-induced coronary arterial relaxation involves activation of the myocyte voltage-gated K⁽⁺⁾ channels and inward rectifier K⁽⁺⁾ channels[J]. Life Sci, 2019, 221:233-240. doi:10.1016/j.lfs.2019.02.028.
[41]	ZHENG L, LIU M, WEI M, et al. Tanshinone IIA attenuates hypoxic pulmonary hypertension via modulating K_V currents[J]. Respir Physiol Neurobiol, 2015, 205:120-128. doi:10.1016/j.resp.2014.09.025.

钾离子通道在低氧性肺动脉高压中的作用及药物干预研究进展

Research progress on the role of potassium channels and drug intervention in hypoxic pulmonary hypertension

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

参考文献 41

相关文章 15

编辑推荐

Metrics

本文评价

[1]	黄愿, 王刚, 李燕玲, 谢萍. 放射性心脏损伤相关信号通路及药物干预的研究进展[J]. 天津医药, 2024, 52(8): 888-892.
[2]	武才鑫, 闫彦, 邓瑗琳, 杜雅敏, 杨振文, 潘晴, 杨帆. 心脏磁共振评估结缔组织病伴重度肺动脉高压的价值[J]. 天津医药, 2024, 52(7): 691-694.
[3]	王慧, 潘晴, 王宙明, 张娜, 杨振文, 魏蔚. 混合性结缔组织病相关肺动脉高压临床特点分析[J]. 天津医药, 2024, 52(7): 701-703.
[4]	杨睿, 魏琼, 孙逸坤, 赵梦竹, 程序, 刘梦华, 张冬梅. 缺氧H9c2来源外泌体对HUVEC增殖、迁移和成管能力的影响[J]. 天津医药, 2024, 52(7): 714-719.
[5]	赵术彤, 丁运, 李月川, 赵晓赟, 耿华, 徐美林. 轻度慢性阻塞性肺疾病的病理特征及其与炎性因子的相关性[J]. 天津医药, 2024, 52(6): 643-647.
[6]	缪春波, 许迎春, 常以芳. 根皮苷通过下调miR-125a-5p减轻缺氧/复氧诱导的H9C2细胞氧化应激和凋亡[J]. 天津医药, 2024, 52(12): 1233-1238.
[7]	魏娜, 李思源, 高苑, 王雪瑞, 肖斌, 牛艺璇, 杨文霞, 刘振兵. 麝香保心丸对缺氧复氧心肌细胞的保护作用及凋亡的影响[J]. 天津医药, 2023, 51(5): 460-463.
[8]	盛思琪, 谢琳, 姜怡邓, 熊建团, 杨安宁, 吴凯, 杨勇, 杨晓明. 转录因子EB在衰老心肌细胞自噬中的作用机制研究[J]. 天津医药, 2023, 51(3): 246-251.
[9]	姜花, 沈延梅, 马驯凯. 下调miR-106a-5p对过氧化氢诱导的心肌细胞损伤及JAK1/STAT3通路的影响[J]. 天津医药, 2023, 51(2): 113-117.
[10]	吕朝阳, 黄婷, 徐在革, 刘惠双, 杨营军, 李真真, 敖文. LncRNA TUG1通过调节miR-181b-5p/PDCD4轴对高糖诱导的心肌细胞凋亡的影响[J]. 天津医药, 2023, 51(12): 1281-1287.
[11]	熊喜成, 王一平, 王刚, 张甜, 包雅丽, 迪娜·艾尼瓦尔, 孙湛. Ferrostatin-1通过抑制铁死亡延缓D-gal诱导的心肌细胞衰老的研究[J]. 天津医药, 2023, 51(1): 19-23.
[12]	郑君毅, 张莹莹, 刘园园, 陈孟英, 郭绪昆. FUNDC1通过调控线粒体分裂影响高糖损伤H9c2心肌细胞凋亡的机制研究[J]. 天津医药, 2022, 50(8): 791-795.
[13]	谭小兵, 王儒仙, 吕美荣, 孙显凤, 吕娜英, 戴青原. 人牙源性iPSCs分化心肌细胞促进急性心肌梗死小鼠心肌修复的研究[J]. 天津医药, 2022, 50(8): 822-826.
[14]	陈旭 , 施凯佳 , 王姣 , 姚姗 , 周田 , 姜成龙 , 陈小盼 . 吡格列酮对高糖高脂诱导大鼠H9C2心肌细胞凋亡的影响及其机制探讨[J]. 天津医药, 2022, 50(4): 337-342.
[15]	钟晓鸣, 刘洪洋, 张蕾, 姚新亮, 鲁雪莉, 许瑾瑾, 程冠昌. lncRNA IGF2-AS调控IGF2对骨髓间充质干细胞心肌样分化的影响[J]. 天津医药, 2022, 50(4): 350-356.